Detalles de la búsqueda
1.
Mesothelioma: Pleural, Version 1.2024.
J Natl Compr Canc Netw
; 22(2): 72-81, 2024 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38503043
2.
Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations.
N Engl J Med
; 383(10): 931-943, 2020 09 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32469185
3.
Targeted Toxicities: Protocols for Monitoring the Adverse Events of Targeted Therapies Used in the Treatment of Non-Small Cell Lung Cancer.
Int J Mol Sci
; 24(11)2023 May 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-37298380
4.
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
N Engl J Med
; 378(22): 2078-2092, 2018 May 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-29658856
5.
Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable stage III non-small-cell lung cancer.
Future Oncol
; 17(10): 1165-1184, 2021 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-33583206
6.
Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Lancet Oncol
; 21(3): 387-397, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32035514
7.
Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
Cancer
; 126(22): 4867-4877, 2020 11 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-32914866
8.
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.
N Engl J Med
; 376(7): 629-640, 2017 02 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-27959700
9.
Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumab.
Acta Oncol
; 59(9): 1058-1063, 2020 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-32762415
10.
Characterization of patients with metastatic non-small-cell lung cancer obtaining long-term benefit from immunotherapy.
Future Oncol
; 15(23): 2743-2757, 2019 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-31339060
11.
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
N Engl J Med
; 373(2): 123-35, 2015 Jul 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-26028407
12.
Pembrolizumab plus Chemotherapy in Lung Cancer.
N Engl J Med
; 379(11): e18, 2018 09 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-30207917
13.
Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After Five Years of Follow-Up.
J Thorac Oncol
; 2024 Apr 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-38642841
14.
Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC.
J Thorac Oncol
; 2024 Mar 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-38461929
15.
Prevention of chemotherapy-induced nausea and vomiting and the role of neurokinin 1 inhibitors: from guidelines to clinical practice in solid tumors.
Anticancer Drugs
; 24(2): 99-111, 2013 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-23165435
16.
Real-World Treatment Patterns and Outcomes of First-Line Immunotherapy Among Patients With Advanced Nonsquamous NSCLC Harboring BRAF, MET, or HER2 Alterations.
JTO Clin Res Rep
; 4(10): 100568, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37744307
17.
What is the ideal endpoint in early-stage immunotherapy neoadjuvant trials in lung cancer?
Ther Adv Med Oncol
; 15: 17588359231198446, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37720499
18.
Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC.
JTO Clin Res Rep
; 4(1): 100431, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-36793385
19.
Poziotinib in Treatment-Naive NSCLC Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-Label, Phase 2 Trial (Cohort 4).
J Thorac Oncol
; 18(8): 1031-1041, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-36958688
20.
Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study.
J Thorac Oncol
; 18(2): 181-193, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36307040